Back to search results
NCT07083115

Developing MRI Technologies for Atrial Fibrillation

Enrolling by Invitation
Not specifiedAges 18+Observational
The Cleveland Clinic
~50 participants
Updated 2026-03-23 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Image quality
Measured over At completion of each MRI

Conditions

Atrial Fibrillation (AF)

Explore related trials

Atrial Fibrillation

NCT07083115

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cleveland Clinic

    Cleveland, Ohiono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christopher Nguyen, PhD · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of Atrial Fibrillation

Exclusion

Contraindications to MRI
Contraindications to Gadolinium based contrast agents.

What this trial measures

  • Image qualityAt completion of each MRI

    To demonstrate standard dose (0.05mmol/kg) of Gadopiclenol cardiac MRI significantly improves the enhancement of AF compared with standard dose (0.1mmol/kg) of conventional GBCA agents. Research MRI data will be reviewed against any standard clinical MRI available in the patient's medical record.